Smith, Moore & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Smith, Moore & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,858	Closed	-$234K	–	434
2021 Q3	$234K	Hold	1,858	–	–	0.04%	355
2021 Q2	$252K	Sell	1,858 -10	-0.5%	-$1.31K	0.04%	339
2021 Q1	$253K	Sell	1,868 -36	-2%	-$5.39K	0.04%	319
2020 Q4	$268K	Buy	1,904 +74	+4%	+$9.48K	0.05%	279
2020 Q3	$204K	Buy	+1,830	New	+$205K	0.04%	301

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Smith, Moore & Co's XBI Position: Q4 2021 in Review

Smith, Moore & Co sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2021, closing a stake of 1,858 shares — an estimated $234K sold.

Smith, Moore & Co first reported a position in XBI in Q3 2020 and held it in 5 quarters. The position peaked at $268K in Q4 2020. 702 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

Smith, Moore & Co reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2021 after selling out during the quarter.
Smith, Moore & Co sold 1,858 State Street SPDR S&P Biotech ETF shares in Q4 2021, an estimated $234K.
Smith, Moore & Co first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 5 quarters.
Smith, Moore & Co's State Street SPDR S&P Biotech ETF position peaked at $268K in Q4 2020.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on Smith, Moore & Co's 13F filing for Q4 2021, filed 8 Feb 2022.